- Employers: Entry-Level Applicants Are Just About Useless
- Walmart vs. Costco: How Do They Really Compare?
- Tesla Pops on GM Rumor (Update 1)
- Putting a Fingerprint on Every Bullet
- Why Apple Sucks as an Investment, but Amazon Doesn't
Article
Rethinking Idenix Pharma in Wake of Bristol's Hep C Blow Up
The two Hep C drugs are similar enough chemically to warrant caution.
07:00AM 08/06/12
Article
Gilead Sciences Firing On All Cylinders
Gilead posted strong second-quarter earnings and is moving ahead aggressively with its new hepatitis C drugs.
07:00AM 07/30/12
Article
The Health Care Short Sales That Never Fit
Valuation shorts can be investment quicksand, explains TheStreet columnist Nate Sadeghi.
07:00AM 07/23/12
Article
Eli Lilly, Verastem and the Defenders of Shareholder Value
TheStreet contributor Nate Sadeghi calls for healthcare investors to start acting like owners.
07:07AM 07/16/12
Article
Onyx Pharma Must Start Delivering Profits
With a second cancer drug approval looming, Onyx can join a select group of successful and profitable biotech companies.
08:10AM 07/10/12
Article
ObamaCare Upheld: Health Care Stock Winners and Losers
TheStreet's Nathan Sadeghi-Nejad examines which health care stocks benefit from the Supreme Court's decision to uphold health care reform.
11:38AM 06/28/12
Article
Arena Pharma And The Fat Lady's Song
Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.
11:13AM 06/25/12
Article
Alkermes Needs to Build on Drug Delivery Success
An undervalued stock could move higher if Alkermes continues to grow through acquisitions.
07:00AM 06/18/12
Article
A Reckoning Approaches: Supreme Court and Obama's Healthcare Reform Law
Six possible outcomes of the Court's healthcare ruling and what it means for healthcare stocks.
07:09AM 06/11/12
Article
Bad Romance: Glaxo's Brutal Courtship of Human Genome Sciences
Contributor Nathan Sadeghi-Nejad offers tips to Glaxo's CEO on how to woo the stubborn HGSI into marriage.
07:45AM 06/04/12